NCT03463681已完成2 期
A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2018年6月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- progression free survival (PFS)
研究概览
简要总结
This is an open label single arm, multicenter, phase II study designet To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •One previous anticancer treatment with a PD1/PDL1 inhibitor, as monotherapy or in combination with an angiogenesis inhibitor or anti CTLA 4, in both setting first line or adjuvant ( in this case patient having recurrence during the adjuvant treatment or within 6 months after therapy with PD1-PD-L1 therapy)
- •Age ≥18 years
- •Patients with histological diagnosis of predominant clear cells renal cell carcinoma
- •Measurable disease (as per RECIST 1.1 criteria) with documented radiological progression
- •Fertile women (<2 years after last menstruation) and men of childbearing potential must use effective methods of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilisation) during the study and for 4 months after the last dose of study treatment
- •All sites of disease including brain metastases (non symptomatic)
- •Karnofsky performance status ≥ 70%
- •Life expectancy greater than 3 months
- •The required values at baseline are as follows:
- •Absolute neutrophil count >1.5 x 109 /L,
- •Platelet count > 100 x 109 /L,
- •Haemoglobin > 9g/dl,
- •Total bilirubin < 1.5 upper limit of normal (ULN);
- •AST, ALT<2.5 ULN in patients without liver metastases, <5 ULN in patients with liver metastases;
- •serum creatinine < 2.0 mg/dl, amylase and lipase <1.5 ULN 11- Female subjects of childbearing potential must not be pregnant at screening
排除标准
- •Major surgical procedure within 28 days prior to study treatment start
- •Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix, meningiomas)
- •Clinically significant cardiovascular disease, for example cerebrovascular accidents (<6 months), myocardial infarction (<6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication
- •Recent (within the 30 days prior to randomisation) treatment with another investigational drug or participation in another investigational study
- •Symptomatic brain metastasis
- •History of other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates use of an investigational drug or patient at high risk from treatment complications
- •PT or INR and PTT >1.5 times the Upper Normal Limit of the institution (patient who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists).For patients on warfarin, close monitoring of at least weekly evaluations will be performed, until INR is stable based on a measurement at pre-dose, as defined by the local standard of care
- •Previous or concomitant radiotherapy in the lesion parameter of disease
- •Previous radiotherapy or other locoregional antitumoral treatment performed within 21 days before the study recruitment
- •Uncontrolled hypertension (>= 160 mmHg systolic and/or 90 mmHg diastolic) while receiving chronic medication
- •Inability to swallow tablets or capsules
- •Female subject who is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women
- •Known history of human immunodeficiency virus (HIV) infection, active hepatitis B, or active hepatitis C.
- •Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
研究组 & 干预措施
Cabozantinib
Experimental
all subjects will recieve open label Cabozantinib 60 mg orally once daily
干预措施: Cabometyx (Drug)
结局指标
主要结局
progression free survival (PFS)
时间窗: 28 month
To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
次要结局
- overall survival (OS)(28 month)
- objective response rates (ORR)(28 month)
- safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(28 month)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Cabozantinib (XL184) in Patients With Relapsed or Refractory MyelomaRelapsed or Refractory Multiple MyelomaNCT01866293Memorial Sloan Kettering Cancer Center11
终止
2 期
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate CancerNCT04631744Weill Medical College of Cornell University4
进行中（未招募）
1 期
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.MedDRA version: 21.0Level: PTClassification code: 10073251Term: Clear cell renal cell carcinoma Class: 100000004864CTIS2024-514058-59-00Fondazione IRCCS Istituto Nazionale Dei Tumori49
进行中（未招募）
1 期
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreatedPatients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitorsMedDRA version: 21.0Level: PTClassification code 10073251Term: Clear cell renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000582-36-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI49
终止
2 期
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate CancerProstate Cancer AdenocarcinomaNon-MetastaticProstate CancerNCT03964337Duke University3